Shire hires Tulstrup to head MPS franchise
This article was originally published in Scrip
Shire has appointed Soren Tulstrup senior vice-president and MPS (mucopolysaccharides) franchise lead for it Human Genetic Therapies business. He will report to Sylvie Grégoire, president of Shire HGT. Mr Tulstrup is the former president and CEO of Santaris Pharma, before which he spent over a decade at Merck & Co. He is currently vice-chair of European Biopharmaceutical Enterprises.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.